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Lack of antimicrobial activity of sodium heparin for treating experimental
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Objective To elucidate the potential antimicrobial activity of sodium heparin in the treatment of catheter
infection using the antibiotic-lock technique.
Methods We performed in vitro studies of the antibiotic susceptibility, stability and synergy of sodium heparin,
vancomycin and ciprofloxacin. Efficacy studies were performed in a new animal model of Staphylococcus aureus
catheter-related infection in which infection was produced via the endoluminal route. White New Zealand
rabbits were surgically implanted with a sylastic catheter into the inferior cava vein. Immediately afterwards,
infection was induced by filling and locking the catheters with 0.7 mL of broth culture containing 108 colony-
forming units of S. aureus. Eighteen hours later the antibiotic-lock technique was started. Treatment groups
were: control without treatment, sodium heparin at 2500 IU/mL, vancomycin at 2500 mg/L, ciprofloxacin at
1000 mg/L, vancomycin plus heparin and ciprofloxacin plus heparin.
Results Sodium heparin showed an MIC90 higher than 6000 UI/mL against S. aureus causing catheter
infection. Studies of antimicrobial synergy by the time-kill method between vancomycin and ciprofloxacin at
MIC with sodium heparin at 2500 IU/mL showed no interactions. Vancomycin (2000 mg/mL) and
ciprofloxacin (1000 mg/mL) in a solution containing sodium heparin (2500 IU/mL) were stable at 37 8C for a
72-h period. Two sets of in vivo experiments were carried out using differents strains of S. aureus. In both cases,
sodium heparin showed no therapeutic efficacy when compared to control group and did not increase the
antibiotic efficacy when used in combination with vancomycin or ciprofloxacin.
Conclusion Sodium heparin lacked antibacterial activity against S. aureus causing catheter-related infections.
Keywords Catheter-related infection, antibiotic-lock, animal model of infection, S. aureus; heparin,
vancomcyn, ciprofloxacin
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INTRODUCTION
Conservative management of catheter-related bacteremia in
patients who need permanent vascular access is a goal that
produces considerable benefits [2–4]. Catheter salvage implies
sterilization of the catheter plus appropriate treatment of the
bacteremia. The antibiotic-lock technique (ALT), which con-
sists of locking high antibiotic concentrations within the cathe-
ter, avoids the risk of systemic toxicity [5] and is well recognized
for treating catheter infection [6–9]. The fact that the antibiotic
is locked within the catheter raises doubts about the suitability
of adding heparin to avoid thrombosis. There is some con-
troversy as to the physical compatibility [10,11] and the in vitro
[12] and in vivo [13–15] activity of sodium heparin used alone
or in combination with certain antibiotics. Another matter of
interest is the potential contribution of heparin to the eradica-
tion of bacteria that adhere to the catheter and form biolayers
embedded in a fibrin network, a common occurence in cathe-
ter-related infection [16–21].
Staphylococci are the most frequent bacteria associated with
catheter-related infection (CRI). Vancomycin and ciproflox-
acin have certain chemical characteristics that favor their use in
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the treatment of staphylococcal CRI by means of the ALT
[6,22]. The aim of this study was to evaluate the in vitro activity
of sodium heparin alone and combined with vancomycin or
ciprofloxacin against Staphylococcus aureus. Additionally, we tried
to elucidate the potential influence of sodium heparin on
efficacy of vancomycin or ciprofloxacin in a new experimental
model of S. aureus CRI by ALT.
MATERIALS AND METHODS
In vitro studies
Susceptibility studies
By means of the tube macrodilution method [23], we deter-
mined the minimum inhibitory concentrations (MICs) and
minimum bactericidal concentrations (MBCs) of sodium
heparin, vancomycin and ciprofloxacin against 20 strains of
S. aureus isolated from patients with catheter-related septicemia.
Heparin for testing was prepared by adding 0.9% saline to
sodium heparin powder. Vancomycin and ciprofloxacin were
prepared in solutions with distilled water that was fresh on the
day used. Drugs were supplied by the following manufacturers:
heparin by Sociedad Espan˜ola de Especialidades Farmaco-Ter-
apeu´ticas S.A. (Barcelona, Spain), vancomycin by Dista S.A.
(Madrid, Spain) and ciprofloxacin by Quı´mica Farmaceu´tica
Bayer S.A. (Barcelona, Spain). Inocula were prepared from
logarithmic-phase cultures to yield a final concentration of
105 CFU/mL and inoculated into serial dilutions of sodium
heparin (range: 100–6000 IU/mL), vancomycin or ciproflox-
acin (range: 0.06–32 mg/L) in cation-adjusted Mu¨eller–Hinton
broth [23]. The control strain was S. aureus ATCC29213.
Subcultures were used to confirm purity and quantify inocula.
The MIC was determined as the lowest concentration to inhibit
the visible growth of the test organism. The MBC was deter-
mined from subcultures on 5% sheep blood Columbia agar
plates of 0.05 mL each from the control tube, from the first tube
with visible growth, and from all tubes without visible growth.
The MBC was defined as the lowest concentration of antibiotic
that killed 99.9% of the original inoculum [23]. All determi-
nations were done in duplicate.
Synergy studies
The in vitro synergy of sodium heparin plus vancomycin or
ciprofloxacin against five strains of S. aureus was tested by the
time-kill method. Killing curves were determined with cation
Mueller–Hinton broth with an inoculum size of 107 CFU/mL
in the logarithmic phase of growth. We used vancomycin and
ciprofloxacin at concentrations equal to the MIC, both alone
and in combination with 2500 IU/mL of sodium heparin. After
0, 4 and 24 h of incubation at 35 8C in room air, 0.05 mL
samples of serial dilutions (to 106) were subcultured on 5%
sheep blood Columbia agar plates. After incubation for 48 h at
35 8C in room air, the bacterial counts expressed as the log10
CFU/mL were plotted against time. Each experiment was run
three times in duplicate and included controls of growth with-
out antibiotic. Synergism and antagonism were defined as an at
least 100-fold increase or decrease in killing at 24 h with the
combinations, as compared with the most active single drug
[24].
Antibiotic stability studies
To investigate the physical stability of vancomycin or cipro-
floxacin in mixtures with sodium heparin, we prepared solu-
tions containing 2500 IU of sodium heparin and 2000 mg/L of
vancomycin or 1000 mg/L of ciprofloxacin aseptically. The
solutions were elaborated in the same way as those prepared in
clinics for treating catheter infection with the ALT. Vancomy-
cin, ciprofloxacin and sodium heparin were obtained, respec-
tively, from comercially available preparations, Diatracin (Dista
S.A., Alcobendas, Madrid, Spain), Baycip (Quı´mica Farm-
aceu´tica Bayer, Barcelona, Spain) and Heparina ROVI (Rovi
S.A., Madrid, Spain).
Antibiotic-heparin solutions were placed in sterile glass tubes
at 37 8C in room air and samples obtained sequentially in
triplicate at 0, 24, 48 and 72 h were frozen at 80 8C for
posterior analysis. All samples were assayed on the same day.
Vancomycin concentrations were determined by polarization
immunofluorescence, following the instructions of the manu-
facturer (Axsym Analyzer, Abbott Laboratories, Chicago, IL,
USA). The sensitivity of the assay was 1.25 mg/L and the
coefficients of variation were less than 7%. Ciprofloxacin
determinations were carried out by the disk-plate bioassay
method [25] using Klebsiella pneumoniae (ATCC 1031) as the
test microorganism and Antibiotic Medium 5 (Difco Labora-
tories, Detroit, MI, USA) as the growth medium. Standard
curves were determined with solutions of ciprofloxacin (0.15,
0.3, 0.5, 0.7 and 0.9 mg/L) in rabbit serum. The standard
samples were assayed in quintuplicate, and test samples were
assayed in triplicate. The linearity (r2) of standard curve was 0.9.
The sensitivity of the assay was 0.04 mg/mL, and the between-
and within-day coefficients of variations for replicates (n ¼ 7)
at 0.2 and 4 mg/L were less than 5%.
Results are expressed as the meanSD mg/L of antibiotic in
solution with sodium heparin.
In vivo studies
For the in vivo studies, we have developed a new animal model
in which infection was produced with the catheter in place,
using the endoluminal route.
Standardization of the animal model of CRI
Twenty white New Zealand rabbits (weight, approximately
1.9–2.1 kg) were anesthesized by intramuscular injection of
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ketamine at 100 mg/kg and xylazene at 20 mg/kg. A right
laterocervical incision was made to expose the jugular vein
bifurcation. The internal jugular vein was distally ligated, and
catheterized with a sterile silicone catheter (Tube silicone,
SILASTIC, ID/OD:0.45/0.77 inch, Dow Corning Corpora-
tion, MI, USA). The proximal end of the catheter had a
removable hub (Vygon 1298.20, Laboratories Pharmaceutiques
Vygon, Ecoulen, France) which was connected to a three-way
luer-lock device for fluid administration (Connecta Plus 3,
Ohmeda, Helsingborg, Sweden). The catheter was introduced
up to 8 cm to ensure allocation of the tip into the inferior cava
vein. The catheter was secured with silk sutures and patency was
ensured with aspiration and reinjection of blood. The line was
tunnelled subcutaneously and brought to the interscapular
region. The external portion of the catheter was connected
to the removable hub and then to the three-way luer-lock
device. Immediately after the catheter was filled and locked
with 0.7 mL of broth culture containing 108 CFU/mL of
N16.2 S. aureus. The animals were scheduled to be sacrificed
with a lethal intravenous injection of sodium pentothal in two
groups (10 animals each), at 18 and 48 h after infection. Before
sacrificing the animals, evidence of infection was sought by
paired quantitative blood cultures [26,27]. For this purpose,
1 ml of blood simultaneously sampled from the catheter
(CQBC) and from the marginal ear vein (PQBC), was quanti-
tatively cultured in soy trypticase agar by the pour-plate
method. Then, the catheters were aseptically removed and
the distal 4 cm were microbiologically evaluated with the
roll-plate method [15], quantitative culture of the endoluminal
flushing, and quantitative culture after sonication. Broth flush
culture was performed by a modification of the method of Cleri
et al. [28]. Briefly, 2 mL of Mueller–Hinton broth was flushed
twice through the lumen and the flushing was quantitatively
cultured. Subsequently, the tip segment was cultured by the
roll-plate method. Finally, the catheter was longitudinally
bisected to ensure exposition of the internal surface, submerged
in 4 mL of broth and sonicated at 50 Hz for 10 min. Then, serial
decimal dilutions of 0.05 mL samples (to 103) were subcul-
tured on 5% sheep blood Columbia agar plates. After incuba-
tion for 48 h at 37 8C in room air, CFU were counted.
Efficacy studies
Antimicrobial therapy by the ALT was initiated 18 h after
infection and continued for 24 h. One milliliter of blood
was obtained by the marginal ear vein (PQBC) to confirm
the presence of catheter infection. The blood specimen was
mixed with 10 mL of molten trypticase soy agar (BioMe´rieux).
Plates were incubated for 48 h at 37 8C in room air, and the
presence of S. aureus was interpreted as indicative of catheter
infection. Then the inoculum was withdrawn and the catheter
were flushed with 1 mL of saline. The removable connector
system was replaced with a sterile one and the catheters were
filled with 0.7 mL of the antimicrobial solution and locked.
The treatment groups included: control without treatment,
sodium heparin at a concentration of 2500 IU/mL, vancomycin
at 2500 mg/L, ciprofloxacin at 1000 mg/L, vancomycin plus
heparin, and ciprofloxacin plus heparin at the same concentra-
tions. Antibiotic solutions were prepared as described before in
the stability studies. Control animals without treatment were
sacrificed 18 h after infection. The animals of therapeutic
groups were sacrificed 24 h later with a lethal intravenous
injection of sodium pentothal by the marginal ear vein, and
the catheters were aseptically removed for microbiological
processing as described above. The antibiotic was withdrawn
before culture. Washing was done by centrifugation of the broth
cultures at 2500  g for 10 min. The supernatant was removed
and the bacterial pellet was resuspended in drug-free medium.
We used two washings to ensure extensive drug removal.
Two sets of therapeutical experiments were done with two
differents strains of S.aureus (D22.1 and N16.2).
The MIC/MBC of vancomycin and ciprofloxacin for both
strains were, respectively: D22.1 (0.25/8 mg/L of vancomycin
and 0.25/8 mg/L of ciprofloxacin) and N16.2 (0.25/8 mg/L of
vancomycin and 0.25/4 mg/L of ciprofloxacin).
Analysis of results
Results of the roll-plate method were expressed as number of
negative cultures (CFU < 15) out of total catheters. Quanti-
tative cultures after flushing and sonication of the catheter
were expressed as the mean the standard deviation of the
log10 of CFU of S. aureus recovered. The number of negative
cultures out of total was also shown. We considered quantitative
cultures to be negative if total colony counts were lower
than 40 for flushing (1.6 log) or lower than 80 for sonication
(1.9 log).
Differences in log10 CFUs of staphylococci were analyzed
statistically using the Kruskall–Wallis test and Wilcoxon Mann–
Whitney U rank-sum analysis, and results were corrected
for multiple comparisons [29]. Comparisons of the frequencies
of sterilization of the catheters were made by Fisher’s exact test.
P-values of less than or equal to 0.05 were considered sig-
nificant;
RESULTS
In vitro studies
Susceptibility studies
The MIC50, MIC90, MBC50 and MBC90 of vancomycin,
ciprofloxacin and sodium heparin against 20 strains of S. aureus
causing catheter-related bacteremia are presented in Table 1.
Sodium heparin showed no in vitro activity against S. aureus at
concentrations achievable in clinical practice ( 5000 IU/mL).
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Studies of antimicrobial synergy
The studies of antimicrobial synergy between vancomycin or
ciprofloxacin at MIC with sodium heparin at concentration of
2500 UI/mL showed no interactions. Heparin did not inhibit
the growth of S. aureus tested at 4 and 24 h. The addition of
heparin to the above antibiotics did not show any antimicrobial
interaction, either antagonism or synergism. Figure 1 shows the
results of the time-kill curves of the strains used in the in vivo
studies.
Antibiotic stability studies
The antibiotics were physically stable in a mixture with
heparin through the entire period of observation. At 72 h of
solution preparation, antibiotic concentrations remained very
similar to the initial values, with less than 10% variation
(Table 2).
In vivo studies
Standardization of the animal model of CRI
The results of the standardization of the animal model are
shown in Table 3. All animals were infected with positive
catheter tips cultures by both qualitative and quantitative meth-
ods. With infection by endoluminal route, both catheter sur-
faces (internal and external), became colonized by high bacteria
colony counts that caused bacteremia in the rabbit. The
degree of catheter infection was similar at 18 or 48 h after
the inoculum was placed inside the catheter. However, two of
10 animals (20%) died when infection was maintained more
than 18 h.
Therapeutic experiments
The results of therapeutic groups are shown in Table 4 (S. aureus
D22.1) and Table 5 (S. aureus N16.2). In both cases, sodium
heparin showed no therapeutic efficacy when compared with
the control group without antibiotic treatment. Ciprofloxacin
was the most active single agent for sterilizing the catheter and
lowering bacterial counts in the animals. Addition of sodium
heparin did not increase antibiotic efficacy, but it decreased the
ciprofloxacin catheter sterilization rate in one in vivo experi-
ment (Table 5, S. aureus N16.2). In our animal model of CRI,
vancomycin showed therapeutic efficacy only against one strain
(Table 4, S. aureus D22.1).
Table 1 Susceptibility to vancomycin, ciprofloxacin and sodium heparin of
20 strains of S. aureus causing catheter-related sepsis
MIC50 MBC50 MIC90 MBC90
Vancomycin 0.25 4 0.5 8
Ciprofloxacin 0.5 8 1 8
Sodium heparin > 6000 > 6000
Results of MICs and MBCs were expressed as mg/L for vancomycin and
ciprofloxacin, or UI/m for heparin.
Figure 1 Time-kill curves of the strains used in the in vivo studies. S. aureus
D 22.1 (A) and N16.2 (B). Sodium heparin at 2500 UI/mL, vancomycin at
0.25mg/L (A) and 2mg/L (B), ciprofloxacin at 0.25mg/L (A,B).*,Control;
*, heparin 2500;~, vancomycin MIC;^, ciprofloxacin MIC;$, vancomy-
cinþ heparin;&, ciprofloxacinþheparin.
Table 2 Vancomycin and ciprofloxacin concentrations (mg/L) in a solution
with sodiumheparin (2500IU/mL) at different intervals of time
0 h 24 h 48 h 72 h
Vancomycin 2096  74 1917  90 1841 18 1967  67
Ciprofloxacin 1010  20 970  40 1045  50 1045  45
Results represent the mean SD of the three aliquots analyzed simulta-
neously.
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DISCUSSION
The aim of this study was to evaluate the efficacy of sodium
heparin and the in vivo and in vitro interactions of heparin and
vancomycin or ciprofloxacin in solutions for treating CRI using
the ALT. This practical therapeutic approach has caused con-
cern about the stability of different antibiotics in solution with
heparin and has raised questions about the antimicrobial con-
tribution of heparin, in itself.
Vancomycin and ciprofloxacin in solutions containing
sodium heparin remain stable at least for 72 h at 37 8C as de-
monstrated by our study and others [17,30]. The manufacturer’s
recommendations and data from the literature state that van-
comycin can precipitate when administered simultaneously
with heparin [12,13,24,31, 32]. We found that this depends
on the concentrations of these two components. In a scale of
inverse serial decimal dilutions, from concentrations of 4500
mg/L of vancomycin and 500 IU/mL of sodium heparin to
concentrations of 500 mg/L vancomycin and 4500 IU of
sodium heparin, the solutions showed no macroscopic preci-
pitation (data not shown). Our investigations into the compat-
ibility of vancomycin and ciprofloxacxin with heparin showed
small variations (less than 10%) in antibiotic concentrations over
a 72-h period. Thus, the antibiotic/heparin solution inside the
Table 3 Standardization of a S. aureus catheter-related sepsis animal model
Death/total CQBC/PQBCa Roll-plate negative/totalb Flushingc Sonicatedc
18 h 0/10 10/10 0/10 4.1 1.2 4.5  1.1
48 h 2/10 8/8 0/8 4.0  1.5 4.1 1.3
Microbiological results were obtained at18 and 48 h since infection was provoked. CQBC/PQBC: catheter quantitative blood cultures/peripheral quantitative
blood cultures. aResults expresed the number of test positive/number animals tested. A test is considered positivewhen colony forming units per ml in CQBC/
PQBC ratio is higher than 5. bNegative was considered a number of colony forming units< 15. cResults of the quantitative cultures are expresed as the mean
SDof the log10 of total number of the colony forming units recovered.
Table 4 Results of treatment of S. aureus (D22.1) experimental catheter-related sepsis
Flushing Sonicated
Treatment groups Death/total Roll-plate negative/totalc Negative/totald Countse Negative/total Countse
Control 0/9 0/9 0/9 4.67  1.08 0/9 4.86  1.41
Heparin 0/7 0/7 0/7 5.56  1.49 0/7 5.69  0.60
Vancomycin 0/12 8/12a 6/12a 2.23  0.70a 5/12 2.94  1.11a
Ciprofloxacin 1/13 10/12a 7/12a 2.34  1.07a 512a 2.42  0.67a
Vancomycinþ heparin 1/11 7/10a 3/10 2.80  1.41 5/10a 3.17  1.71b
Ciprofloxacinþ heparin 0/12 9/12a 8/12a 2.29  1.03 8/12a 2.49  1.24a
aP < 0.05 versus control and heparin. bP < 0.05 versus heparin. cNegative is considered a number of colony forming units< 15. dWe considered a result of a
quantitative cultures to be negative if total colony counts were lower than 40 for flushing (1.6 log) or lower than 80 for sonication (1.9 log). eResults of quanti-
tative cultures are expressed as themeanSDof the log 10 of total number of the colony forming units recovered at the end of treatment.
Table 5 Results of treatment of S. aureus (N16.2) experimental catheter-related sepsis
Flushing Sonicated
Treatment groups Death/total Roll-plate negative/totalc Negative/totald Countse Negative/total Countse
Control 0/14 0/14 0/14 4.40  0.81 0/14 4.59  0.71
Heparin 0/8 0/8 0/8 4.03  0.57 0/8 5.04  0.98
Vancomycin 2/13 0/11 0/11 4.60  0.87 0/11 4.92  0.92
Ciprofloxacin 0/15 6/15 8/15 2.47  0.96 a 6/15 3.61 1.61b
Vancomycinþ heparin 1/10 0/9 0/9 3.95  0.85 0/9 4.85  0.50
Ciprofloxacinþ heparin 1/15 0/14 0/14 3.72  0.75 0/14 5.05  0.68
aP < 0.05 versus all groups; bP < 0.05 versus ciprofloxacinþheparin. cNegative is considered a number of colony forming units<15. dWe considered a result
of a quantitative cultures to be negative if total colony counts were lower than 40 for flushing (1.6 log) or lower than 80 for sonication (1.9 log). eResults of
quantitative cultures are expressed as the meanSDof the log 10 of total number of the colony forming units recovered at the end of treatment.
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cathetercanbemaintainedfor3 dayswithoutchanging.Recently,
others authors have confirmed the stability of vancomycin, cefa-
zolin, ticarcillin-clavulanic acid and ciprofloxacin combined with
heparinafter incubationinvitroat25or37 8Cfor intervalsofupto
10 days. However, the stability of other b-lactam antibiotics,
combined with heparin, such as ceftazidime, was demonstrated
tobe less [30]. Inour study, we did not assay the stabilityof heparin
under the same conditions as the antibiotics. However, Henrick-
son and colleagues [10] evaluated the stabilityof the anticoagulant
activity of heparin in combination with vancomycin in room air
and at 4 8C for periods up to 6 weeks and found no loss of
anticoagulant activity. These facts are important when treatment
of catheter infection is planned in an outpatient setting, since
unnecessary catheter manipulations can be avoided.
A sodium heparin MIC higher than 6000 IU/mL precludes
its clinical use as an antimicrobial agent. The maximum con-
centration of sodium heparin achievable from trade preparations
in clinical practice is 5000 IU/mL. For this reason, we did not
investigate sodium heparin antimicrobial activity at higher
concentrations.
Our synergy studies by the time-kill method did not demon-
strate any in vitro interactions between sodium heparin and
vancomycin or ciprofloxacin. However, the potential role of
heparin in the sterilization of a plastic device has been tested in
vivo, where it might show beneficial effects even though the
susceptibility tests and synergy studies demonstrated its lack of
antibacterial activity against S. aureus.
Catheters inserted in a vein are prone to the formation of a
fibrin sheet over the plastic surface that favors colonization by
microorganisms, their multiplication protected from the defen-
sive mechanisms of the host, and finally the appearance of
clinical manifestations of infection [33]. Heparin could theo-
retically improve the therapeutic effectiveness of an antibiotic
treatment by facilitating penetration of the antmicrobial agent
through the fibrin sheet. This hypothesis merited validation in
an in vivo setting and, for this reason, we developed the animal
model of catheter-related infection. The main characteristics of
this model are that infection was provoked by the endoluminal
route after the catheter was inserted and the animal had no
alterations in immunologic function or in the mechanisms of
fibrin deposition. This physiopathology is comparable to the
most frequent situation in humans who have long-term cathe-
terization [33]. Our animal model is easy to establish, is
reproducible and demonstrates bacterial counts similar to those
obtained in processed catheter tips recovered from patients with
catheter-related bacteremia [27].
Experimental animal infection was well established by 18 h
after the bacterial inoculum was placed inside the catheter. A
48-h delay in beginning therapeutic interventions was not
associated with stronger catheter infection, but two of 10
animals died of S. aureus sepsis. For these reasons, we decided
to begin treatment after 18 h of infection.
Ciprofloxacin was the most active single agent for sterilizing
catheters and lowering bacterial colony counts in both in vivo
experiments. Ciprofloxacin was also able to sterilize the exter-
nal surface in 10 out of 12 catheters infected with S. aureus
D22.1, and in six out 15 infected with S. aureus N16.2. This
result is surprising because animals were not treated with
systemic antibiotics. Perhaps the presence of antibiotic inside
the catheter prevents the migration of bacteria to the external
surface, thereby facilitating the removal of bacteria by the host
defensive mechanisms; or it may be that passive diffusion of
antibiotic clears the external surface. These are only hypotheses
that this study cannot resolve. However, we know that the
absence of bacterial growth found when the external surface of
the catheters was rolled over an agar plaque was not due to the
presence of antibiotic in the catheter, because they were
extensively flushed before rolling.
Vancomycin was less effective than ciprofloxacin for steriliz-
ing catheters. In general, glycopeptides are less effective than
b-lactams and other antibiotics for treating deep S. aureus
infections. Moreover, vancomycin has shown high MBCs when
tested with bacteria adhering to plastic surfaces [20,34]. The
theoretical anti-infective properties of sodium heparin were not
confirmed in our animal model of S. aureus catheter infection.
In vivo, heparin administered alone showed no antibacterial
activity, as demonstrated by lack of catheter sterilization and the
fact that bacterial counts in recovered catheters were identical in
heparin-treated animals and controls. Heparin in combination
with antibiotics did not improve the bacterial eradication of
vancomycin or ciprofloxacin used alone. It is also noteworthy
that addition of heparin was found to worsen the antibacterial
efficacy of the most active antibiotic (ciprofloxacin) in one of
the two strains of S. aureus tested in vivo (Table 5).
In summary, sodium heparin lacks antibacterial activity both
in vitro and in vivo against of S. aureus causing CRI. Heparin
did not add any therapeutic benefit to antibiotics in the treat-
ment of CRI using the ALT. Heparin lock should be used when
the risk of catheter thrombosis is high but not based on criteria
of antimicrobial properties. If there is catheter thrombosis in
addition to infection, fibrinolitics should be tried in an attempt
to improve therapeutic efficacy of antibiotics [35,36].
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